Clinical trials
Lupus Erythematosus, Systemic clinical trials
Below are recruiting lupus erythematosus, systemic clinical trials, each written for real people, not researchers. We’re tracking 260 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07041801RecruitingPhase 1/Phase 2
Stem cell therapy for lupus patients
This trial tests whether a type of stem cell from umbilical cords can help people with systemic lupus erythematosus (an autoimmune disease). It aims to find a new way to reduce lupus symptoms and improve quality of life.
Shenzhen, GuangdongAges 18–65 - NCT07043153Recruiting
Predicting lupus disease activity with blood tests
This study looks at whether two blood markers (AGR and PNI) can help track how active lupus is. You may be eligible if you have lupus and are not pregnant or have other serious health conditions.
SohagAges 18 years+ - NCT06710717RecruitingPhase 1
CD19 CAR T-cells for severe lupus
This early-phase trial tests whether a patient's own immune cells (T-cells) that are modified to target a protein called CD19 can help people with severe lupus that hasn't improved with other treatments. The goal is to reduce lupus activity and possibly achieve remission.
Bandar Tun Razak, Kuala LumpurAges 18–65 - NCT07011043RecruitingPhase 1
Study of budoprutug for lupus
This trial tests an investigational drug called budoprutug for people with active systemic lupus erythematosus (SLE) that has not improved after at least two previous treatments. The goal is to see if it can help control lupus symptoms.
Allen, TexasAges 18–65 - NCT07010835RecruitingPhase 1/Phase 2
Study of YK012 for moderate to severe lupus
This trial tests a new drug, YK012, for people with moderate to severe lupus. It aims to see if the drug can reduce disease activity and improve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT06340750RecruitingPhase 1
BAFF CAR-T cells for lupus that hasn't improved with standard treatments
This trial tests a new type of cell therapy called BAFF CAR-T cells (LMY-920) for lupus that hasn't gotten better with standard treatments. It aims to see if these special immune cells can help calm the overactive immune system in lupus.
Columbus, OhioAges 18–65 - NCT07000916Recruiting
Follow-up study for new arthritis in kids and young adults
This study follows children and young adults newly diagnosed with certain types of arthritis or related conditions to learn more about their health over time. It may help doctors better understand how these diseases progress and how treatments work.
BrusselsAges 2–50 - NCT06978647RecruitingPhase 1
YTS109 cell therapy for stubborn autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT06977724RecruitingPhase 1
Testing a new drug for lupus, sjogren's, and rheumatoid arthritis
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
Avon Park, FloridaAges 18–75 - NCT06946485RecruitingEarly Phase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.
Nanjing, JiangsuAges 18–65 - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06927219Recruiting
Lupus registry for patients and caregivers
This study creates a registry for people with lupus and their families. It helps researchers learn more about lupus and improve care. You or your child can join if you have a lupus diagnosis.
Washington D.C., District of ColumbiaAges Any age - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
La Jolla, CaliforniaAges 18–70 - NCT06917742RecruitingPhase 1
Study of CPTX2309 for rheumatoid arthritis and lupus
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
Herston, QueenslandAges 18–65 - NCT06916806RecruitingPhase 1
Study of AZD5492 for lupus, myositis, or rheumatoid arthritis
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
Anniston, AlabamaAges 18–70 - NCT06921239Recruiting
HLA antibodies in lupus patients
This study looks for certain immune markers (HLA antibodies) in stored blood samples from people with lupus. It may help doctors understand how the immune system behaves in lupus.
AmiensAges 18 years+ - NCT06888973Enrolling by invitationPhase 1/Phase 2
Stem cell infusion for autoimmune diseases
This clinical trial is testing if infusions of special stem cells (called mesenchymal stem cells) can help people with certain autoimmune diseases where standard treatments have not worked well enough. It is an early-phase study in Pakistan for adults (and some children for one condition) with rheumatoid arthritis, lupus, systemic sclerosis, ankylosing spondylitis, or dermatomyositis/polymyositis.
RawalpindiAges 18–50 - NCT06881290RecruitingPhase 1
Vunakizumab for mild to moderate lupus
This trial tests a new drug called Vunakizumab for people with mild to moderate lupus that affects the skin or joints. It aims to see if adding this drug to your current treatment can help control symptoms better.
Beijing, Beijing MunicipalityAges 18–65 - NCT06875960RecruitingPhase 4
Continuing deucravacitinib for people with lupus
This study lets people who have already finished a previous trial of deucravacitinib continue taking the medicine. It is for adults with lupus, including skin-only forms of the disease, to see if long-term treatment remains safe and helpful.
Farmington, ConnecticutAges 18–75 - NCT06857214RecruitingPhase 1
GNC-038 antibody study for moderate to severe lupus
This trial tests a new antibody treatment, GNC-038, for people with moderate to severe lupus. It aims to see if it's safe and effective. You must have stable lupus treatment and active B cells in your blood.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06839976RecruitingPhase 1/Phase 2
CART19 cell therapy for lupus
This trial tests a treatment called CART19, where your own immune cells are modified in a lab to target and destroy faulty B cells that cause lupus inflammation. It's for young people with active lupus that hasn't improved with standard treatments.
Philadelphia, PennsylvaniaAges 10–29 - NCT06822881RecruitingPhase 1
Cell therapy for lupus and scleroderma
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Beijing, Beijing MunicipalityAges 18–60 - NCT06804057Recruiting
SLE drug safety registry for adults with lupus
This registry tracks the safety and effectiveness of lupus treatments over time. If you have SLE and are starting a new treatment or were recently diagnosed, joining helps doctors learn which medicines work best.
Waltham, MassachusettsAges 18 years+ - NCT06789107RecruitingPhase 1
Blinatumomab for severe childhood lupus
This trial tests a drug called blinatumomab for children with active lupus that hasn't improved with standard treatments. It aims to see if this immunotherapy can help calm the immune system and reduce lupus activity.
Hangzhou, ZhejiangAges 5 years+
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus erythematosus, systemic?
- Yes. Clin2 currently lists 260 recruiting lupus erythematosus, systemic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus erythematosus, systemic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus erythematosus, systemic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.